Hospital capacity and post-transplant survival after allogeneic bone marrow transplantation: analysis of data from the Japan Society for Hematopoietic Cell Transplantation
Hospital capacity and post-transplant survival after allogeneic bone marrow transplantation: analysis of data from the Japan Society for Hematopoietic Cell Transplantation
复制标题
同种异体骨髓移植后的医院容量和移植后存活率：日本造血细胞移植学会数据分析
DOI：
--
复制
发表时间：
2000
影响因子：
4.8
通讯作者：
Mine Harada
中科院分区：
文献类型：
--
作者：
Keitaro Matsuo;Nobuyuki Hamajima;Y. Morishima;Mine Harada
使用日本造血细胞移植学会（JSHCT）积累的数据集，研究医院容量与异基因骨髓移植（allo-BMT）后生存率之间的关系。受试者为3134例在1991年至1997年期间接受首次allo-BMT的患者，报告给JSHCT。根据allo-BMT的累积医院经验，将他们分为三组：低容量（容量）（LV; 1025例）、中等容量（容量）（MV; 26-75例）和高容量（容量）（HV; 1076例）。使用比例风险模型，研究住院经验与第100天早期生存（D100 S）和总生存（OS）的相关性。对于白血病患者，还分析了无白血病生存期（LFS）。当HV被定义为参考组时，所有受试者的OS风险比（HR）为MV 1.10（95%置信区间; 0.97-1.25）和LV 1.25（1.08-1.44）。D100 S的HR为1.20（0.96-1.51），MV和1.40（1.08-1.80），LV。在白血病病例中观察到OS和D100 S的较大值。来自同胞供体的骨髓移植后生存率明显受到医院经验的影响，但无关供体的情况并非如此。这些研究结果表明，移植团队的规模应予以考虑，以改善一般同胞BMT的结果。骨髓移植（2000）26，1061-1067。
The association between hospital capacity and survival after allogeneic bone marrow transplantation (allo-BMT) was examined using the dataset accumulated by the Japan Society of Hematopoietic Cell Transplantations (JSHCT). The subjects were 3134 patients who received first allo-BMTs between 1991 and 1997 reported to the JSHCT. They were divided into three groups by cumulative hospital experience of allo-BMTs: low volume (capacity) (LV; ⩽25 cases), moderate volume (capacity) (MV; 26–75 cases) and high volume (capacity) (HV; ⩾76 cases). Using a proportional hazards model, the association of hospital experience with early survival at day 100 (D100S), and overall survival (OS) were examined. For leukemia patients, leukemia-free survival (LFS) was also analyzed. When HV was defined as the reference group, the hazard ratios (HRs) of OS for all subjects were 1.10 (95% confidence interval; 0.97–1.25) for MV and 1.25 for LV (1.08–1.44). The HRs with D100S were 1.20 (0.96–1.51) for MV and 1.40 (1.08–1.80) for LV. Larger values were observed for OS and D100S in cases of leukemia. Survival after BMT from sibling donors was clearly influenced by hospital experience, but this was not the case from unrelated donors. These findings suggest that size of the transplant team should be considered in order to improve the outcome of sibling BMT in general. Bone Marrow Transplantation (2000) 26, 1061–1067.
异体骨髓移植治疗骨髓增生异常综合征的最新进展。
影响因子：
2.6
作者：
Anderson,JE;Appelbaum,FR;Storb,R
通讯作者：
Storb,R
治疗白血病的 HLA 相同同胞骨髓移植是否应该仅限于大型中心？
影响因子：
20.3
作者：
Horowitz,MM;Przepiorka,D;Champlin,RE;Gale,RP;Gratwohl,A;Herzig,RH;Prentice,HG;Rimm,AA;Ringdén,O;Bortin,MM
通讯作者：
Bortin,MM